Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Biomarkers and Clinical Targeting of the PI3 Kinase and VEGF Pathways

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 10 of 10
Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC)
José Baselga
Mass. General Hospital Cancer Center Administration, Boston, MA, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
Discussant
Gordon B Mills
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
Discussant
Carlos L Arteaga
Vanderbilt-Ingram Cancer Ctr., Nashville, TN, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor
Jordi Rodon
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
Discussant
Lewis C. Cantley
Weill Cornell Medical College, New York, NY, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study
Dejan Juric
Massachusetts General Hospital Cancer Center, Boston, MA, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
Discussant
Sarat Chandarlapaty
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy
Charles S Fuchs
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
Discussant
Herbert I Hurwitz
Duke Univ. Medical Ctr., Durham, NC, United States
from AACR Annual Meeting 2013 on April 7, 2013 3:00 PM-5:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 10 of 10